On September 30, the capital state learned thatBaide Medical treatmentSubmit a prospectus to the Hong Kong Stock Exchange for listing on the Hong Kong main board IPO.

According to the prospectus, Baide Medical is a developer and provider of microwave ablation medical devices for minimally invasive treatment of tumors in China. The company's proprietary microwave ablation medical devices are used to treat benign and malignant tumors with increasing incidence in China, including thyroid nodules, liver cancer, lung cancer and breast masses.

At present, Pak Medical's product supply and pipeline products mainly include microwave ablation therapeutic instruments and microwave ablation needles used in conjunction with therapeutic instruments.

During the track record period, all revenue from Pak Tak Medical came from sales in China, and the company's products were eventually sold to hospitals for final consumption by patients. Most of these hospitals are level II and III hospitals covering 22 provinces, municipalities and autonomous regions in China. In the first six months of 2021, there are 230 hospitals purchasing products from companies in China, of which 131 are Class III hospitals.

In terms of finance, in the three financial years from 2018 to 2020 and the first half of 2021, the income of Pak Tak Medical was 52.321 million (RMB, the same below), 85.029 million, 118 million and 74.671 million yuan respectively, and the corresponding net profit was-60.013 million,-49.661 million, 46.62 million and 27.006 million yuan, respectively.

It is worth noting that the company's future growth and success depend to a large extent on its ability to successfully market its products to hospitals directly or through distributors or distributors.

On the other hand, the company's bid in the open tender may not be successful and the company's products may not be selected, including: the company's price is not competitive, and the company's products fail to meet the technical or quality requirements implemented by the hospital. or lower than competitive products in clinical benefits, and so on. If the company fails to win the bid in the open tender, the company's ability to expand its overall sales network may be limited, which may have a significant adverse impact on the company's business and operating results.